Latest news

Thumbnail image for ViiV kicks off PhIII trial of two-drug HIV regimen

ViiV kicks off PhIII trial of two-drug HIV regimen

ViiV Healthcare, an HIV specialist firm majority owned by GlaxoSmithKline, has announced the launch of a late-stage study investigating the effectiveness of a two-drug regimen programme in patients with HIV.

9th February 2018

Thumbnail image for Biogen reveals Tysabri failure in stroke trial

Biogen reveals Tysabri failure in stroke trial

Biogen has confirmed that it will not pursue further development of Tysabri in acute ischemic stroke (AIS) after a mid-stage study missed primary and secondary efficacy goals.

9th February 2018

Thumbnail image for GSK happy with 3 percent rise in 2017 sales

GSK happy with 3 percent rise in 2017 sales

GlaxoSmithKline has reported a sales hike of 3 percent at constant exchange rates (CER*) for 2017, after growth was recorded across all of its three global businesses.

8th February 2018

Thumbnail image for Theravance Ireland signs deal with Janssen Biotech

Theravance Ireland signs deal with Janssen Biotech

Theravance Biopharma Ireland has signed a global co-development and commercialisation deal with Janssen Biotech focusing on new treatments for inflammatory intestinal conditions, including ulcerative colitis and Crohn’s disease.

8th February 2018

Thumbnail image for Scotland’s TCB inks CAR-T deal with Japan’s NIPRO

Scotland’s TCB inks CAR-T deal with Japan’s NIPRO

Scotland’s TC Biopharm (TCB) has secured a major investment from Japan with a deal centered on developing a novel gamma-delta CAR-T therapy to treat cancer, as well as a grant from Scottish Enterprise worth £2.7 million to fund preclinical activities.

7th February 2018

Thumbnail image for Ireland procures Sobi therapies for all haemophilia patients

Ireland procures Sobi therapies for all haemophilia patients

The Republic of Ireland has become the first country in Europe to switch its entire population with haemophilia A and B treated with short-acting replacement clotting factors to Swedish Orphan Biovitrum’s (Sobi) extended half-life therapies Elocta and Alprolix.

7th February 2018

Thumbnail image for NICE restricts NHS use of Roche’s IPF drug Esbriet

NICE restricts NHS use of Roche’s IPF drug Esbriet

Cost regulators for NHS therapies in England and Wales have now issued final guidelines endorsing the use of Roche’s Esbriet to treat patients with idiopathic pulmonary fibrosis (IPF), but only in those with moderate to severe forms of the disease.

6th February 2018

Thumbnail image for Gov’t confirms HPV jabs for men who have sex with men

Gov’t confirms HPV jabs for men who have sex with men

Men who have sex with men (MSM) will be offered protection against the human papillomavirus (HPV) via a national vaccination programme in England due to be rolled out latest this year, the government has confirmed.

6th February 2018

Thumbnail image for MHRA expands use of Tillotts’ Entocort

MHRA expands use of Tillotts’ Entocort

The Medicines and Healthcare Products Regulatory Agency (MHRA) has expanded the approved uses of Tillotts Pharma’s Entocort to include the induction of remission in patients with active microscopic colitis (MC).

6th February 2018

Thumbnail image for Opdivo/Yervoy combo beats chemo on PFS in lung cancer

Opdivo/Yervoy combo beats chemo on PFS in lung cancer

Bristol-Myers Squibb has revealed that a combination of its immunotherapies Opdivo and Yervoy was superior to chemo alone in keeping disease progression at bay in patients with non-small cell lung cancer (NSCLC).

6th February 2018

Previous  --   12 13 14 15 16 17 18 19 20 21   --  Next

Download our apps

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Download